A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC

Trial Details

NCT ID

NCT07416695

Phase

PHASE1

Sponsor

Shanghai Henlius Biotech

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• HLX3901

Locations (sample)

• Beijing, China|39.9075,116.39723
• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF);…
• Aged ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;
• Histologically or cytologically confirmed advanced small cell lung cancer or neuroendocrine carcinoma; patients with advanced small cell lung cance…
• At least one measurable lesion as per RECIST 1.1 within 4 weeks prior to the first administration;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.